A detailed history of Retirement Planning CO Of New England, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Retirement Planning CO Of New England, Inc. holds 11,216 shares of BMY stock, worth $653,107. This represents 0.29% of its overall portfolio holdings.

Number of Shares
11,216
Previous 10,634 5.47%
Holding current value
$653,107
Previous $441,000 31.52%
% of portfolio
0.29%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $23,082 - $30,118
582 Added 5.47%
11,216 $580,000
Q2 2024

Aug 08, 2024

BUY
$40.25 - $52.99 $16,824 - $22,149
418 Added 4.09%
10,634 $441,000
Q1 2024

May 06, 2024

SELL
$47.98 - $54.4 $138,278 - $156,780
-2,882 Reduced 22.0%
10,216 $554,000
Q4 2023

Feb 12, 2024

BUY
$48.48 - $57.85 $44,698 - $53,337
922 Added 7.57%
13,098 $672,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $8,683 - $9,709
150 Added 1.25%
12,176 $706,000
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $1,783 - $1,980
28 Added 0.23%
12,026 $769,000
Q1 2023

Apr 21, 2023

SELL
$65.71 - $74.53 $3,548 - $4,024
-54 Reduced 0.45%
11,998 $831,000
Q4 2022

Feb 03, 2023

BUY
$68.48 - $81.09 $1,506 - $1,783
22 Added 0.18%
12,052 $867,000
Q3 2022

Oct 19, 2022

BUY
$0.13 - $76.84 $83 - $49,331
642 Added 5.64%
12,030 $855,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $3,703 - $4,078
-51 Reduced 0.45%
11,388 $876,000
Q1 2022

May 06, 2022

SELL
$61.48 - $73.72 $13,833 - $16,587
-225 Reduced 1.93%
11,439 $835,000
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $625,540 - $729,233
11,664 New
11,664 $727,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Retirement Planning CO Of New England, Inc. Portfolio

Follow Retirement Planning CO Of New England, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Retirement Planning CO Of New England, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Retirement Planning CO Of New England, Inc. with notifications on news.